Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 12Parkinson Disease 4, Autosomal Dominant Lewy Body 8Melanoma 6Carcinoma, Renal Cell 6Neoplasms 5Neoplasm Metastasis 3Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Liver Neoplasms 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Metastatic Castration-Resistant Prostate Cancer 1

Interventions

Gemcitabine 13Cisplatin 10pembrolizumab 7Oxaliplatin 5Leucovorin 5Fluorouracil 5durvalumab 4Paclitaxel 4Nivolumab 3Injections 3Immune Checkpoint Inhibitors 3Capecitabine 3camrelizumab 2Docetaxel 2Cetuximab 2Carboplatin 2130-nm albumin-bound paclitaxel 2tremelimumab 1surufatinib 1spartalizumab 1silmitasertib 1regorafenib 1pertuzumab 1manganese chloride 1lenvatinib 1irinotecan sucrosofate 1folfirinox 1devimistat 1derazantinib 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Biliary Tract Neoplasms × lenvatinib × Clear all
NCT05327582 2022-04-14

An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC

Chinese PLA General Hospital

Phase 1/2 Unknown
65 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡